Log In
BCIQ
Print this Print this
 

GLX1112

  Manage Alerts
Collapse Summary General Information
Company Glialogix Inc.
DescriptionImproved formulation of an existing undisclosed FDA-approved
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat progressive multiple sclerosis (MS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today